Inova Health System and Roswell Park Comprehensive Cancer Center Join KIYATEC Clinical Trial to Predict Patient Response to Cancer Drugs Prior to Treatment

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Mar 15, 2019 01:02 pm
GREENVILLE, SC. -- 

KIYATEC, Inc. today announced that the company has opened Inova Health System (Inova) and Roswell Park Comprehensive Care Center as sites for its U.S. clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in ovarian, glioblastoma (GBM) and rare cancer patients.

“The addition of Inova Health System and Roswell Park Comprehensive Cancer Center to our clinical study is an important milestone as we continue on the path to determine the best drug option for cancer patients before they begin their treatment journey,” said Matthew Gevaert, CEO of KIYATEC. “Both hospitals are known for their excellence in clinical research and patient care, most notably in ovarian cancer. Not only will this be significant for our trial, it underscores their commitment to finding the best, personalized care for their patients.”

The 3D-PREDICT clinical study analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically-relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs. Evidence from the company’s earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors. The 3D-PREDICT study is anticipated to continue through 2022. Details on the trial can be found on Clinicaltrials.gov.

“Roswell Park has the unique distinction of being the first clinical center in the world to focus exclusively on cancer, and we are continuously seeking new and improved methods to provide the best care for our patients,” said Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director, chair of gynecologic oncology and executive director of the Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, and lead investigator. “The 3D-PREDICT trial presents an opportunity to utilize an emerging technology for identifying biomarkers of response in our ovarian cancer immunotherapy research.”

Inova has already accrued patients into the trial and G. Larry Maxwell, MD, Chairman of Obstetrics and Gynecology and co-director of Inova’s Women's Health Integrated Research Center (WHIRC) is the lead investigator. Inova Strategic Investments, the strategic investing division of the Inova Health System, is an investor in KIYATEC. The division invests in companies that align with Inova’s strategic priorities of delivering personalized health and healthcare services.

KIYATEC will be exhibiting at the Society for Gynecologic Oncology (SGO) 50th Annual Meeting on Women’s Cancer, which is being held March 16-19, 2019 at the Hawaii Convention Center in Honolulu, Hawaii.

MacDougall
Lauren Arnold, 781-235-3060
larnold@macbiocom.com

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).